Zhang and colleagues have demonstrated that APC mutation was observed in 80% samples in metabolism-associated subtype C1, 67% in subtype C2 and 59% in subtype C3, which may prevent choosing resistant chemotherapeutic drugs for COAD patients with different classification21. This evidence concerns the gene APC and colon adenocarcinoma.